{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:47:11Z","timestamp":1758808031622,"version":"3.44.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.xphs.2025.103918","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T15:56:05Z","timestamp":1753286165000},"page":"103918","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk based qualification of non-mutagenic impurities"],"prefix":"10.1016","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2519-1179","authenticated-orcid":false,"given":"Naseem A","family":"Charoo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed","family":"Untoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Eltigani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2025.103918_bib0001","unstructured":"International Conference on Harmonization (ICH)\u2014Impurities in New Drug Substances Q3A(R2). 2006. Available at:https:\/\/database.ich.org\/sites\/default\/files\/Q3A%28R2%29%20Guideline.pdf. Accessed 10 June 2025."},{"key":"10.1016\/j.xphs.2025.103918_bib0002","unstructured":"International Conference on Harmonization (ICH)\u2014Impurities in New Drug Products Q3B(R2). 2006. Available online:https:\/\/database.ich.org\/sites\/default\/files\/Q3B%28R2%29%20Guideline.pdf. Accessed 10 June 2025."},{"key":"10.1016\/j.xphs.2025.103918_bib0003","unstructured":"International Conference on Harmonization (ICH)- M7(R2), 2023. Guideline On Assessment and Control of DNA Reactive (mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-m7r2-guideline-assessment-and-control-dna-reactive-mutagenic-impurities-pharmaceuticals-limit-potential-carcinogenic-risk-step-5_en.pdf. Accessed 5 June 2025."},{"key":"10.1016\/j.xphs.2025.103918_bib0004","unstructured":"International Conference on Harmonization (ICH)- ICH Q3C, 2016. ICH Q3C (R9) Guideline on impurities: Guideline For Residual Solvents. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-q3c-r9-guideline-impurities-guideline-residual-solvents-step-5_en.pdf. Accessed 12 June 2025."},{"key":"10.1016\/j.xphs.2025.103918_bib0005","unstructured":"International Conference on Harmonization (ICH)-ICH Q3D, 2019. Guideline For Elemental Impurities. Q3D(R2). Available at: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-ich-q3d-elemental-impurities-step-5-revision-2_en.pdf."},{"key":"10.1016\/j.xphs.2025.103918_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2021.104895","article-title":"Harmonized 3Rs-based non-mutagenic impurity qualification study designs developed using the results of an IQ consortium survey","volume":"122","author":"Mitra","year":"2021","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.xphs.2025.103918_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2021.105023","article-title":"Calculating qualified non-mutagenic impurity levels: harmonization of approaches","volume":"126","author":"Graham","year":"2021","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.xphs.2025.103918_bib0008","unstructured":"European medicines Agency (EMA) 2024. Consolidated 3-year Rolling Work Plan For the Non-clinical domain. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/other\/consolidated-3-year-rolling-work-plan-non-clinical-domain-2025-2027_en.pdf. Accessed 12 June 2025."},{"key":"10.1016\/j.xphs.2025.103918_bib0009","unstructured":"FDA MAPP 5017.2 Rev. 1. Manual of Policy and Procedures, Guidance for Assessors; \u201cEstablishing Impurity Acceptance Cri-teria as Part of Specifications for NDAs, ANDAs, and BLAs Based on Clinical Relevance\u201d. 2020. Available at: https:\/\/www.fda.gov\/media\/124859\/download. Accessed 10 November 2021."},{"key":"10.1016\/j.xphs.2025.103918_bib0010","unstructured":"European medicines Agency (EMA) 2024. Reflection Paper On the Qualification of Non-Mutagenic impurities. Draft. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-reflection-paper-qualification-non-mutagenic-impurities_en.pdf. Accessed 12 June 2025."},{"key":"10.1016\/j.xphs.2025.103918_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2019.104524","article-title":"Qualification of impurities based on metabolite data","volume":"110","author":"Weidolf","year":"2020","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"1","key":"10.1016\/j.xphs.2025.103918_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/scipharm90010001","article-title":"Using metabolite data to develop patient centric specification for amide impurity in Vildagliptin tablets","volume":"90","author":"Charoo","year":"2022","journal-title":"Sci. Pharm."},{"key":"10.1016\/j.xphs.2025.103918_bib0013","unstructured":"European medicines Agency (EMA) 2018. Reflection Paper On the Qualification of Non-Mutagenic Impurities. Available at: https:\/\/www.ema.europa.eu\/en\/qualification-non-mutagenic-impurities-scientific-guideline. Accessed 12th June 2025."},{"key":"10.1016\/j.xphs.2025.103918_bib0014","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13321-020-00462-3","article-title":"Maximum common property: a new approach for molecular similarity","volume":"12","author":"Antelo-Collado","year":"2020","journal-title":"J Cheminform"},{"issue":"7","key":"10.1016\/j.xphs.2025.103918_bib0015","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1021\/ci100010v","article-title":"When is chemical similarity significant? The statistical distribution of chemical similarity scores and its extreme values","volume":"50","author":"Baldi","year":"2010","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.xphs.2025.103918_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2024.105645","article-title":"Analysis of non-mutagenic substances in the context of drug impurity assessment - few are potent toxicants","volume":"150","author":"Hasselgren","year":"2024","journal-title":"Regul. Toxicol. Pharmacol"},{"key":"10.1016\/j.xphs.2025.103918_bib0017","unstructured":"International Conference on Harmonisation (ICH), S9, 2008. Guideline: Nonclinical Evaluation For Anticancer Pharmaceuticals. S9. Available at: https:\/\/database.ich.org\/sites\/default\/files\/S9_Guideline.pdf. Accessed 12th June 2025."},{"key":"10.1016\/j.xphs.2025.103918_bib0018","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.yrtph.2016.12.011","article-title":"Management of organic impurities in small molecule medicinal products: deriving safe limits for use in early development","volume":"84","author":"Harvey","year":"2017","journal-title":"Regul Toxicology Pharmacol"},{"key":"10.1016\/j.xphs.2025.103918_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.119018","article-title":"Industry approaches and consideration of clinical relevance in setting impurity level specification for drug substances and drug products","volume":"576","author":"Pokar","year":"2020","journal-title":"Int. J. Pharm"},{"key":"10.1016\/j.xphs.2025.103918_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2024.105647","article-title":"New limits proposed for the management of non-mutagenic impurities","volume":"150","author":"Slikkerveer","year":"2024","journal-title":"Regul. Toxicol. Pharmacol"},{"key":"10.1016\/j.xphs.2025.103918_bib0021","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0300-483X(00)00228-6","article-title":"The use of Haber\u2019s Law in standard setting and risk assessment","volume":"149","author":"Gaylor","year":"2000","journal-title":"Toxicol"},{"key":"10.1016\/j.xphs.2025.103918_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2024.105644","article-title":"Deriving acceptable limits for non-mutagenic impurities in medicinal products - durational adjustments","volume":"150","author":"Kenyon","year":"2024","journal-title":"Regul. Toxicol. Pharmacol"},{"key":"10.1016\/j.xphs.2025.103918_bib0023","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0278-6915(96)00049-X","article-title":"Correlation of structural class with no-observed-effect levels: a proposal for establishing a threshold of concern","volume":"34","author":"Munro","year":"1996","journal-title":"Food Chem. Toxicol."},{"issue":"6","key":"10.1016\/j.xphs.2025.103918_bib0024","first-page":"5708","article-title":"Guidance on the use of the Threshold of toxicological Concern approach in food safety assessment","volume":"17","year":"2019","journal-title":"EFSA J"},{"issue":"2","key":"10.1016\/j.xphs.2025.103918_bib0025","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/toxsci\/kfm058","article-title":"Development of safety qualification thresholds and their use in orally inhaled and nasal drug product evaluation","volume":"97","author":"Ball","year":"2007","journal-title":"Toxicol Sci"},{"issue":"3","key":"10.1016\/j.xphs.2025.103918_bib0026","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.yrtph.2015.03.001","article-title":"Principles for identification of high potency category chemicals for which the dermal sensitisation threshold (DST) approach should not be applied","volume":"72","author":"Roberts","year":"2015","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.xphs.2025.103918_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2020.104732","article-title":"Application of the dermal sensitization threshold concept to chemicals classified as high potency category for skin sensitization assessment of ingredients for consumer products","volume":"117","author":"Nishijo","year":"2020","journal-title":"Regul Toxicol Pharmacol"},{"issue":"2","key":"10.1016\/j.xphs.2025.103918_bib0028","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.yrtph.2010.06.009","article-title":"Evaluation of inhalation TTC values with the database RepDose","volume":"58","author":"Escher","year":"2010","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.xphs.2025.103918_bib0029","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.yrtph.2011.09.005","article-title":"Improvement of the Cramer classification for oral exposure using the database TTC RepDose \u2013 A strategy description","volume":"61","author":"Tluczkiewicz","year":"2011","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.xphs.2025.103918_bib0030","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.yrtph.2016.03.022","article-title":"Inhalation TTC values: a new integrative grouping approach considering structural, toxicological and mechanistic features","volume":"78","author":"Tluczkiewicz","year":"2016","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.xphs.2025.103918_bib0031","doi-asserted-by":"crossref","DOI":"10.3389\/ftox.2020.580347","article-title":"Derivation of new threshold of toxicological concern values for exposure via inhalation for environmentally-relevant chemicals","volume":"2","author":"Nelms","year":"2020","journal-title":"Front Toxicol"},{"key":"10.1016\/j.xphs.2025.103918_bib0033","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13321-017-0194-2","article-title":"SkinSensDB: a curated database for skin sensitization assays","volume":"9","author":"Wang","year":"2017","journal-title":"J Cheminform"},{"key":"10.1016\/j.xphs.2025.103918_bib0034","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.reprotox.2019.07.012","article-title":"ToxRefDB version 2.0: improved utility for predictive and retrospective toxicology analyses","volume":"89","author":"Watford","year":"2019","journal-title":"Reprod Toxicol"},{"issue":"1","key":"10.1016\/j.xphs.2025.103918_bib0035","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13321-017-0247-6","article-title":"The CompTox Chemistry Dashboard: a community data resource for environmental chemistry","volume":"9","author":"Williams","year":"2017","journal-title":"J Cheminform"},{"issue":"1\u20132","key":"10.1016\/j.xphs.2025.103918_bib0036","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ijpharm.2012.03.019","article-title":"Prediction of the human oral bioavailability by using in vitro and in silico drug related parameters in a physiologically based absorption model","volume":"429","author":"Paix\u00e3o","year":"2012","journal-title":"Int J Pharm"},{"issue":"11","key":"10.1016\/j.xphs.2025.103918_bib0037","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1021\/acs.jcim.9b00460","article-title":"Prediction of oral bioavailability in rats: transferring insights from in vitro correlations to (Deep) machine learning models using in silico model outputs and chemical structure parameters","volume":"59","author":"Schneckener","year":"2019","journal-title":"J Chem Inf Model"},{"issue":"1","key":"10.1016\/j.xphs.2025.103918_bib0038","doi-asserted-by":"crossref","first-page":"140","DOI":"10.14573\/altex.2010062","article-title":"NAM-supported read-across: from case studies to regulatory guidance in safety assessment","volume":"38","author":"Rovida","year":"2021","journal-title":"ALTEX"},{"key":"10.1016\/j.xphs.2025.103918_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.tiv.2021.105269","article-title":"Integrate mechanistic evidence from new approach methodologies (NAMs) into a read-across assessment to characterise trends in shared mode of action","volume":"79","author":"Escher","year":"2022","journal-title":"Toxicol in vitro"},{"key":"10.1016\/j.xphs.2025.103918_bib0040","unstructured":"EMA. 2025 New Approach Methodologies EU-IN Horizon Scanning Report. https:\/\/www.ema.europa.eu\/system\/files\/documents\/report\/new-approach-methodologies-eu-horizon-scanning-report-en.pdf."}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354925003703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354925003703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:01:30Z","timestamp":1758805290000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354925003703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0022354925003703"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2025.103918","relation":{},"ISSN":["0022-3549"],"issn-type":[{"type":"print","value":"0022-3549"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk based qualification of non-mutagenic impurities","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2025.103918","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Pharmacists Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103918"}}